CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Bladder Cancer Awareness Month: 2022 Immunotherapy Research Updates

    This Bladder Cancer Awareness Month, discover new research, new treatments, and progress for a future immune to…

    May 4, 2022| CRI Staff
  • Bladder Cancer Awareness Month: 2021 Immunotherapy Research Updates

    This May for Bladder Cancer Awareness Month, we look at new research, new treatments, and how we’re…

    May 1, 2021| CRI Staff
  • Dr. Terence Friedlander Answers Questions on Bladder Cancer and Immunotherapy from the CRI Virtual Immunotherapy Patient Summit

    Terence Friedlander, MD, answers questions about immunotherapy for bladder cancer from the 2020 CRI Virtual Immunotherapy Patient…

    January 18, 2021| CRI Staff
  • Bladder Cancer Awareness Month: 2020 Immunotherapy Research Update

    A changing treatment landscape, new scientific research, and how we’re working toward a future immune to bladder…

    May 23, 2020| CRI Staff
  • How Immunotherapy Is Transforming Bladder Cancer Treatment

    Arjun V. Balar, MD, discusses checkpoint immunotherapy, new FDA approvals, promising new therapies, and clinical trials for…

    May 21, 2020| Arthur N. Brodsky, PhD
  • Shirley Dumont

    Shirley Dumont’s Immunotherapy Story

    Bladder Cancer |  Diagnosed 2008 My doctor calls me the ‘bionic woman.’ This is all through immunotherapy. Shirley’s…
    June 28, 2019| CRI Staff
  • Curtis Garbett

    Curtis Garbett’s Immunotherapy Story

    Bladder Cancer |  Diagnosed 2015 Advancing cancer research and visioning a future immune to bladder cancer Curtis’s Story…
    January 16, 2019| CRI Staff
  • Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer

    Durvalumab marks AstraZeneca’s first immunotherapy approval

    May 5, 2017| Arthur N. Brodsky, PhD
  • Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer

    It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.

    May 19, 2016| Arthur N. Brodsky, PhD
1 2
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute